Clinical trialNCT00626392CompletedPhase 3Interventional

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

SponsorAbbottEnrollment277Dyslipidemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Roopal Thakkar, MD
Abbott
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
Huntsville, Alabama, United States
Facility name not stated
Scottsdale, Arizona, United States
Facility name not stated
Tucson, Arizona, United States
Facility name not stated
Tucson, Arizona, United States
Facility name not stated
Anaheim, California, United States
Facility name not stated
Los Angeles, California, United States
Facility name not stated
Newport Beach, California, United States
Facility name not stated
Stockton, California, United States
Facility name not stated
Vista, California, United States
Facility name not stated
Westlake Village, California, United States
Facility name not stated
Coral Gables, Florida, United States
Facility name not stated
Jacksonville, Florida, United States
Facility name not stated
Miami, Florida, United States
Facility name not stated
Pembroke Pines, Florida, United States
Facility name not stated
West Palm Beach, Florida, United States
Facility name not stated
North Dartmouth, Massachusetts, United States
Facility name not stated
Rochester, New York, United States
Facility name not stated
Charlotte, North Carolina, United States
Facility name not stated
Winston-Salem, North Carolina, United States
Facility name not stated
Penndel, Pennsylvania, United States
Facility name not stated
Johnston, Rhode Island, United States
Facility name not stated
Mt. Pleasant, South Carolina, United States
Facility name not stated
Simpsonville, South Carolina, United States
Facility name not stated
Colleyville, Texas, United States
Facility name not stated
Houston, Texas, United States
Facility name not stated
San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aspirin →Aspirin placeboNiacin extended-release

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Feb 2008
Primary completion: 30 Apr 2008
Completion: 30 Apr 2008
Last update posted: 2 Sept 2009
Registered enrollment: 277
Registry id: NCT00626392

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.